Ozempic, Wegovy, and Other GLP-1 RA Medications

Multiple class-action lawsuits regarding the marketing of GLP-1 RAs were transferred to be heard together as part of multidistrict litigation (MDL). More information on the MDL is below.

Case Name (Date)

In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
24-md-3094, E.D. Penn.
(2024)

Product/Service

Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, Mounjaro, Zepbound, Trulicity and other GLP-1 RA medications

Allegations

Marketing products as weight-loss medications without adequately disclosing that many people stop using them due to their side effects, the medications do not result in meaningful weight loss for up to 15 percent of people, the average weight loss is approximately 10 percent of a person’s body weight, and people need to stay on them to maintain their weight loss